Treatment Options for Alopecia Areata in Children and Adolescents
Paediatr Drugs. 2024 Mar 11. doi: 10.1007/s40272-024-00620-2. Online ahead of print.ABSTRACTAlopecia areata (AA) lifetime incidence is around 2%, with many patients first experiencing symptoms during childhood. However, ritlecitinib is the only FDA-approved treatment for pediatric patients 12 years and older. This review outlines reported topical, injectable, and oral treatment options for pediatric patients with AA. Clinical studies were obtained via a PubMed search using the following search terms: alopecia areata, areata, universalis, or totalis and medication, therapy, treatment, drug, or management. Only studies with ...
Source: Paediatric Drugs - March 11, 2024 Category: Pediatrics Authors: Linnea L Westerkam Diana B McShane Elizabeth L Nieman Dean S Morrell Source Type: research

Treatment Options for Alopecia Areata in Children and Adolescents
Paediatr Drugs. 2024 Mar 11. doi: 10.1007/s40272-024-00620-2. Online ahead of print.ABSTRACTAlopecia areata (AA) lifetime incidence is around 2%, with many patients first experiencing symptoms during childhood. However, ritlecitinib is the only FDA-approved treatment for pediatric patients 12 years and older. This review outlines reported topical, injectable, and oral treatment options for pediatric patients with AA. Clinical studies were obtained via a PubMed search using the following search terms: alopecia areata, areata, universalis, or totalis and medication, therapy, treatment, drug, or management. Only studies with ...
Source: Paediatric Drugs - March 11, 2024 Category: Pediatrics Authors: Linnea L Westerkam Diana B McShane Elizabeth L Nieman Dean S Morrell Source Type: research

Treatment Options for Alopecia Areata in Children and Adolescents
Paediatr Drugs. 2024 Mar 11. doi: 10.1007/s40272-024-00620-2. Online ahead of print.ABSTRACTAlopecia areata (AA) lifetime incidence is around 2%, with many patients first experiencing symptoms during childhood. However, ritlecitinib is the only FDA-approved treatment for pediatric patients 12 years and older. This review outlines reported topical, injectable, and oral treatment options for pediatric patients with AA. Clinical studies were obtained via a PubMed search using the following search terms: alopecia areata, areata, universalis, or totalis and medication, therapy, treatment, drug, or management. Only studies with ...
Source: Paediatric Drugs - March 11, 2024 Category: Pediatrics Authors: Linnea L Westerkam Diana B McShane Elizabeth L Nieman Dean S Morrell Source Type: research

Treatment Options for Alopecia Areata in Children and Adolescents
Paediatr Drugs. 2024 Mar 11. doi: 10.1007/s40272-024-00620-2. Online ahead of print.ABSTRACTAlopecia areata (AA) lifetime incidence is around 2%, with many patients first experiencing symptoms during childhood. However, ritlecitinib is the only FDA-approved treatment for pediatric patients 12 years and older. This review outlines reported topical, injectable, and oral treatment options for pediatric patients with AA. Clinical studies were obtained via a PubMed search using the following search terms: alopecia areata, areata, universalis, or totalis and medication, therapy, treatment, drug, or management. Only studies with ...
Source: Paediatric Drugs - March 11, 2024 Category: Pediatrics Authors: Linnea L Westerkam Diana B McShane Elizabeth L Nieman Dean S Morrell Source Type: research

Practical Approach to Diagnosis and Management of IL-1-Mediated Autoinflammatory Diseases (CAPS, TRAPS, MKD, and DIRA)
Paediatr Drugs. 2024 Mar;26(2):113-126. doi: 10.1007/s40272-023-00615-5. Epub 2024 Feb 20.ABSTRACTSystemic autoinflammatory diseases (SAIDs) are a group of rare genetic and nongenetic immune dysregulatory disorders associated with high morbidity and mortality if left untreated. Therefore, early diagnosis and initiation of targeted treatment is vital in SAID patients to control the disease activity and prevent long-term immune-mediated damage. A specific group of genetically defined SAIDs is associated with increased inflammasome-mediated production of active interleukin (IL)-1. Even though progress in immunobiology and gen...
Source: Paediatric Drugs - February 20, 2024 Category: Pediatrics Authors: Kader Cetin Gedik Zehra Serap Arici Ovgu Kul Cinar Facundo Garcia-Bournissen Micol Romano Erkan Demirkaya Source Type: research

Practical Approach to Diagnosis and Management of IL-1-Mediated Autoinflammatory Diseases (CAPS, TRAPS, MKD, and DIRA)
Paediatr Drugs. 2024 Mar;26(2):113-126. doi: 10.1007/s40272-023-00615-5. Epub 2024 Feb 20.ABSTRACTSystemic autoinflammatory diseases (SAIDs) are a group of rare genetic and nongenetic immune dysregulatory disorders associated with high morbidity and mortality if left untreated. Therefore, early diagnosis and initiation of targeted treatment is vital in SAID patients to control the disease activity and prevent long-term immune-mediated damage. A specific group of genetically defined SAIDs is associated with increased inflammasome-mediated production of active interleukin (IL)-1. Even though progress in immunobiology and gen...
Source: Paediatric Drugs - February 20, 2024 Category: Pediatrics Authors: Kader Cetin Gedik Zehra Serap Arici Ovgu Kul Cinar Facundo Garcia-Bournissen Micol Romano Erkan Demirkaya Source Type: research

Practical Approach to Diagnosis and Management of IL-1-Mediated Autoinflammatory Diseases (CAPS, TRAPS, MKD, and DIRA)
Paediatr Drugs. 2024 Mar;26(2):113-126. doi: 10.1007/s40272-023-00615-5. Epub 2024 Feb 20.ABSTRACTSystemic autoinflammatory diseases (SAIDs) are a group of rare genetic and nongenetic immune dysregulatory disorders associated with high morbidity and mortality if left untreated. Therefore, early diagnosis and initiation of targeted treatment is vital in SAID patients to control the disease activity and prevent long-term immune-mediated damage. A specific group of genetically defined SAIDs is associated with increased inflammasome-mediated production of active interleukin (IL)-1. Even though progress in immunobiology and gen...
Source: Paediatric Drugs - February 20, 2024 Category: Pediatrics Authors: Kader Cetin Gedik Zehra Serap Arici Ovgu Kul Cinar Facundo Garcia-Bournissen Micol Romano Erkan Demirkaya Source Type: research

Practical Approach to Diagnosis and Management of IL-1-Mediated Autoinflammatory Diseases (CAPS, TRAPS, MKD, and DIRA)
Paediatr Drugs. 2024 Mar;26(2):113-126. doi: 10.1007/s40272-023-00615-5. Epub 2024 Feb 20.ABSTRACTSystemic autoinflammatory diseases (SAIDs) are a group of rare genetic and nongenetic immune dysregulatory disorders associated with high morbidity and mortality if left untreated. Therefore, early diagnosis and initiation of targeted treatment is vital in SAID patients to control the disease activity and prevent long-term immune-mediated damage. A specific group of genetically defined SAIDs is associated with increased inflammasome-mediated production of active interleukin (IL)-1. Even though progress in immunobiology and gen...
Source: Paediatric Drugs - February 20, 2024 Category: Pediatrics Authors: Kader Cetin Gedik Zehra Serap Arici Ovgu Kul Cinar Facundo Garcia-Bournissen Micol Romano Erkan Demirkaya Source Type: research

Practical Approach to Diagnosis and Management of IL-1-Mediated Autoinflammatory Diseases (CAPS, TRAPS, MKD, and DIRA)
Paediatr Drugs. 2024 Mar;26(2):113-126. doi: 10.1007/s40272-023-00615-5. Epub 2024 Feb 20.ABSTRACTSystemic autoinflammatory diseases (SAIDs) are a group of rare genetic and nongenetic immune dysregulatory disorders associated with high morbidity and mortality if left untreated. Therefore, early diagnosis and initiation of targeted treatment is vital in SAID patients to control the disease activity and prevent long-term immune-mediated damage. A specific group of genetically defined SAIDs is associated with increased inflammasome-mediated production of active interleukin (IL)-1. Even though progress in immunobiology and gen...
Source: Paediatric Drugs - February 20, 2024 Category: Pediatrics Authors: Kader Cetin Gedik Zehra Serap Arici Ovgu Kul Cinar Facundo Garcia-Bournissen Micol Romano Erkan Demirkaya Source Type: research

Practical Approach to Diagnosis and Management of IL-1-Mediated Autoinflammatory Diseases (CAPS, TRAPS, MKD, and DIRA)
Paediatr Drugs. 2024 Mar;26(2):113-126. doi: 10.1007/s40272-023-00615-5. Epub 2024 Feb 20.ABSTRACTSystemic autoinflammatory diseases (SAIDs) are a group of rare genetic and nongenetic immune dysregulatory disorders associated with high morbidity and mortality if left untreated. Therefore, early diagnosis and initiation of targeted treatment is vital in SAID patients to control the disease activity and prevent long-term immune-mediated damage. A specific group of genetically defined SAIDs is associated with increased inflammasome-mediated production of active interleukin (IL)-1. Even though progress in immunobiology and gen...
Source: Paediatric Drugs - February 20, 2024 Category: Pediatrics Authors: Kader Cetin Gedik Zehra Serap Arici Ovgu Kul Cinar Facundo Garcia-Bournissen Micol Romano Erkan Demirkaya Source Type: research

Practical Approach to Diagnosis and Management of IL-1-Mediated Autoinflammatory Diseases (CAPS, TRAPS, MKD, and DIRA)
Paediatr Drugs. 2024 Mar;26(2):113-126. doi: 10.1007/s40272-023-00615-5. Epub 2024 Feb 20.ABSTRACTSystemic autoinflammatory diseases (SAIDs) are a group of rare genetic and nongenetic immune dysregulatory disorders associated with high morbidity and mortality if left untreated. Therefore, early diagnosis and initiation of targeted treatment is vital in SAID patients to control the disease activity and prevent long-term immune-mediated damage. A specific group of genetically defined SAIDs is associated with increased inflammasome-mediated production of active interleukin (IL)-1. Even though progress in immunobiology and gen...
Source: Paediatric Drugs - February 20, 2024 Category: Pediatrics Authors: Kader Cetin Gedik Zehra Serap Arici Ovgu Kul Cinar Facundo Garcia-Bournissen Micol Romano Erkan Demirkaya Source Type: research

Practical Approach to Diagnosis and Management of IL-1-Mediated Autoinflammatory Diseases (CAPS, TRAPS, MKD, and DIRA)
Paediatr Drugs. 2024 Mar;26(2):113-126. doi: 10.1007/s40272-023-00615-5. Epub 2024 Feb 20.ABSTRACTSystemic autoinflammatory diseases (SAIDs) are a group of rare genetic and nongenetic immune dysregulatory disorders associated with high morbidity and mortality if left untreated. Therefore, early diagnosis and initiation of targeted treatment is vital in SAID patients to control the disease activity and prevent long-term immune-mediated damage. A specific group of genetically defined SAIDs is associated with increased inflammasome-mediated production of active interleukin (IL)-1. Even though progress in immunobiology and gen...
Source: Paediatric Drugs - February 20, 2024 Category: Pediatrics Authors: Kader Cetin Gedik Zehra Serap Arici Ovgu Kul Cinar Facundo Garcia-Bournissen Micol Romano Erkan Demirkaya Source Type: research

Practical Approach to Diagnosis and Management of IL-1-Mediated Autoinflammatory Diseases (CAPS, TRAPS, MKD, and DIRA)
Paediatr Drugs. 2024 Mar;26(2):113-126. doi: 10.1007/s40272-023-00615-5. Epub 2024 Feb 20.ABSTRACTSystemic autoinflammatory diseases (SAIDs) are a group of rare genetic and nongenetic immune dysregulatory disorders associated with high morbidity and mortality if left untreated. Therefore, early diagnosis and initiation of targeted treatment is vital in SAID patients to control the disease activity and prevent long-term immune-mediated damage. A specific group of genetically defined SAIDs is associated with increased inflammasome-mediated production of active interleukin (IL)-1. Even though progress in immunobiology and gen...
Source: Paediatric Drugs - February 20, 2024 Category: Pediatrics Authors: Kader Cetin Gedik Zehra Serap Arici Ovgu Kul Cinar Facundo Garcia-Bournissen Micol Romano Erkan Demirkaya Source Type: research

Practical Approach to Diagnosis and Management of IL-1-Mediated Autoinflammatory Diseases (CAPS, TRAPS, MKD, and DIRA)
Paediatr Drugs. 2024 Mar;26(2):113-126. doi: 10.1007/s40272-023-00615-5. Epub 2024 Feb 20.ABSTRACTSystemic autoinflammatory diseases (SAIDs) are a group of rare genetic and nongenetic immune dysregulatory disorders associated with high morbidity and mortality if left untreated. Therefore, early diagnosis and initiation of targeted treatment is vital in SAID patients to control the disease activity and prevent long-term immune-mediated damage. A specific group of genetically defined SAIDs is associated with increased inflammasome-mediated production of active interleukin (IL)-1. Even though progress in immunobiology and gen...
Source: Paediatric Drugs - February 20, 2024 Category: Pediatrics Authors: Kader Cetin Gedik Zehra Serap Arici Ovgu Kul Cinar Facundo Garcia-Bournissen Micol Romano Erkan Demirkaya Source Type: research

Practical Approach to Diagnosis and Management of IL-1-Mediated Autoinflammatory Diseases (CAPS, TRAPS, MKD, and DIRA)
Paediatr Drugs. 2024 Mar;26(2):113-126. doi: 10.1007/s40272-023-00615-5. Epub 2024 Feb 20.ABSTRACTSystemic autoinflammatory diseases (SAIDs) are a group of rare genetic and nongenetic immune dysregulatory disorders associated with high morbidity and mortality if left untreated. Therefore, early diagnosis and initiation of targeted treatment is vital in SAID patients to control the disease activity and prevent long-term immune-mediated damage. A specific group of genetically defined SAIDs is associated with increased inflammasome-mediated production of active interleukin (IL)-1. Even though progress in immunobiology and gen...
Source: Paediatric Drugs - February 20, 2024 Category: Pediatrics Authors: Kader Cetin Gedik Zehra Serap Arici Ovgu Kul Cinar Facundo Garcia-Bournissen Micol Romano Erkan Demirkaya Source Type: research